News

Pfizer will continue providing full funding for the costs of research to discover and develop novel small molecule RORgamma modulators. Target for the treatment of autoimmune diseases, RORgamma

Merck Serono Global Research and Early Development head Bernhard Kirschbaum said the platform recognizes the complexity of cancer, which requires diverse approaches to enable alternative therapeutic interventions. "In

Following the US Food & Drug Administration approval of Dr. Reddy’s ANDA for Lamotrigine XR tablets, the company has launched Lamotrigine Extended-Release tablets. The Lamotrigine XR tablets are

The open label, single-arm, multicenter trial will enroll 80 patients in the US, Canada and Europe to evaluate enzalutamide as a single agent against AR-positive, TNBC. All patients

As part of the agreement, DHK plans to offer Arrayit genomic testing services by extending national network of 800 American Medical Center (AMC) facilities and include medical doctors,

Suitable for pharmacists, the new development can be used in laboratories and early clinical trials, while the filling parameters of the series can be easily scaled-up to production

The supplement is designed to protect against axon degeneration damage or trauma persistent during the contact sports. Niagen is the brand of nicotinamide riboside that is believed to

Completely integrated with BioClinica’s product suite and 21 CFR Part 11 compliant, the new platform offers one easy tool to access multiple eClinical applications, as well as analyze

The formulation received Japan manufacturing and marketing authorization on 15 February 2013, and has been placed on the country’s National Health Insurance (NHI) drug price list on 21